Person
Bob Langer
Bob Langer, also called Robert Langer, is a scientist who spoke with Lex Fridman about medicine, drug development, tissue engineering and how medical ideas become products. He described the 1976 Science paper he wrote with Judah Folkman on blood vessel growth inhibitors. He noted that Avastin, the first approved drug of this type, won FDA approval in 2004.
Langer also covered the cost and stages of drug trials, citing Tufts as estimating that a new drug costs over $2 billion. He said his lab has encapsulated insulin-producing cells and made microchips that release drugs on a signal. He also discussed patents, work with the Gates Foundation, and his former students.
1 episodes · 22 quoted claims
Robert Langer and Judah Folkman published a 1976 paper in Science describing some of the first angiogenesis (blood vessel growth) inhibitors, isolated from cartilage.
“we found one, it wasn't purified, but we found one that did work, and that paper, that was the paper I mentioned in science in 1976.”
Lex Fridman Podcast · 0:15:33
Avastin, the first approved drug of this angiogenesis-blocking type, was approved by the FDA in 2004, 28 years after the 1976 work.
“in 2004, 28 years after we started, the first one of those, Avastin, got approved by the FDA.”
Lex Fridman Podcast · 0:18:25
Langer explains that blood vessels grow into tumors and help them grow larger and spread.
“And if you have cancer, blood vessels grow into the tumor, and that's part of what enables the tumor to get bigger.”
Lex Fridman Podcast · 0:14:20
Langer says that when Judah Folkman first proposed starving tumors by cutting off blood vessels, many people thought he was crazy.
“when Dr. Folkman, my boss, first proposed it, it wasn't, a lot of people thought he was pretty crazy.”
Lex Fridman Podcast · 0:19:42
Langer cites Tufts as estimating that developing a new drug costs over $2 billion.
“which according to tufts to make a new drug costs over $2 billion right now and nobody would even come close to giving you that money”
Lex Fridman Podcast · 0:38:52
Langer says human clinical trials are almost always the largest expense in drug development.
“usually proving that something new is safe and effective in people is almost always the biggest expense.”
Lex Fridman Podcast · 0:39:59
Langer describes phase one trials as testing safety and phase two trials as testing effectiveness, each in a small number of patients.
“A phase one trial to show that it's safe in small number of patients. A phase two trial to show that it's effective in a small number of patients”
Lex Fridman Podcast · 0:40:34
Langer says phase three trials test safety and effectiveness in a large number of patients.
“and a phase three trial to show that it's safe and effective in a large number of patients”
Lex Fridman Podcast · 0:40:34
Langer's lab has encapsulated insulin-producing beta cells so they are protected while still responding to glucose.
“one of the things that we've done is encapsulate what are called beta cells. Those are insulin producing cells in a way that they're safe and protected.”
Lex Fridman Podcast · 0:24:19
Langer's lab has made microchips that release a drug when sent a signal.
“we, for example, have made what I'll call intelligent microchips that can, you know, where you can send a signal and, you know, release drug in response to that signal.”
Lex Fridman Podcast · 0:24:59
Langer says he and Jay Vacanti pioneered the use of scaffolds on which cells grow for tissue engineering.
“having generally some type of scaffold. That's what Jay Vacanti and I started many, many years ago.”
Lex Fridman Podcast · 0:29:31
Langer says engineered skin has been approved by the FDA.
“skin's already been made and approved by the FDA. There are advanced clinical trials, like what are called phase three trials”
Lex Fridman Podcast · 0:31:11
Langer says engineered skin products have been approved for burn victims and patients with diabetic skin ulcers.
“they've been approved for burn victims and for patients with diabetic skin ulcers.”
Lex Fridman Podcast · 0:31:58
Langer describes CRISPR as built on a bacterial mechanism for destroying viruses, which became a tool to cut and paste genes.
“there's a mechanism by which bacteria are able to destroy viruses and that understanding that leads to machinery to put, you know, to sort of cut and paste genes”
Lex Fridman Podcast · 0:35:52
Langer says patent applicants negotiate with the United States Patent and Trademark Office, which may reject applications several times.
“And then you go back and forth with the USPTO, that's the United States Patent and Trademark Office.”
Lex Fridman Podcast · 0:42:21
Langer says his lab writes a disclosure for MIT's technology transfer office, which passes it to patent attorneys.
“we write something up what's called a disclosure we give it to mit's technology transfer office they then give it to some patent attorneys”
Lex Fridman Podcast · 0:41:46
Langer says his lab works with the Gates Foundation to extend medicines to people in the developing world.
“which is something that our lab has been doing with the gates foundation or trying to do”
Lex Fridman Podcast · 0:27:43
Langer says philanthropist David Koch funded cancer research partly because he had prostate cancer.
“David Koch was very interested in cancer research. And part of that was that he had cancer and prostate cancer.”
Lex Fridman Podcast · 0:52:46
Langer says Bill Gates chose to focus his philanthropy on medicines and vaccines for people in the developing world.
“he thought about helping people in the developing world and medicines and different things like that, like vaccines”
Lex Fridman Podcast · 0:53:19
MIT's mechanical engineering department hired Gio Traverso, a molecular biologist and gastroenterologist who had been a fellow with Langer.
“mechanical engineering department just had a search and they hired Gio Traverso, who was one of my, he was a fellow with me, but he's actually a molecular biologist and a gastroenterologist.”
Lex Fridman Podcast · 0:56:16
David Edwards, a former Langer postdoc and Harvard professor, started Cafe Art Sciences.
“You have to go to see some of David Edwards' stuff. He was one of my postdocs and he's a professor at Harvard, but he also started Cafe Art Sciences.”
Lex Fridman Podcast · 0:59:19
Langer says about 18 of his former students are in the National Academy of Engineering and 16 in the National Academy of Medicine.
“I think 18 are in the National Academy of Engineering, 16 in the National Academy of Medicine.”
Lex Fridman Podcast · 1:00:13